ライフサイエンスコーパス: TAVI

1 TAVI (United Kingdom Transcatheter Aortic Valve Implanta

2 TAVI and SAVR readmission rates were also compared for p

3 TAVI for patients with CKD stage 4 is still considered c

4 TAVI for severe AS produces a coronary hemodynamic impro

5 TAVI improves microcirculatory function regardless of th

6 TAVI induces an immediate decrease in hyperemic microvas

7 TAVI is feasible in patients with CKD5D and in KT.

8 TAVI patients had invasive pressure gradient assessments

9 TAVI provides a unique opportunity to compare the activa

10 TAVI was successfully performed in all patients.

11 TAVI with or without a cerebral protection device (filte

12 TAVI-PVE occurred at a slightly higher rate than reporte

13 TAVI-PVE was most frequent in the first year after impla

14 Of 1936 TAVI patients (mean age 81.6 years, 52% male), 68 (3.5%)

15 ting System was used to propensity match 617 TAVI and 1981 SAVR patients using numerous patient risk

16 Implantation of a TAVI was performed in 42 patients (97.7%), and 8 patient

17 After TAVI, there were no differences in the short form-12 hea

18 After TAVI, transthoracic echocardiography is performed to ass

19 urvival was 83.4% after SAVR and 72.0% after TAVI (P=0.0015), whereas freedom from major adverse card

20 +/- 0.17 cm(2) to 1.67 +/- 0.41 cm(2) after TAVI and 1.40 +/- 0.25 cm(2) at 5 years (p for post-TAVI

21 events was 80.9% after SAVR and 67.3% after TAVI (P<0.001).

22 urvival was 97.1% after SAVR and 97.4% after TAVI (P=0.82).

23 g hyperemia in both groups, before and after TAVI (group 1) and before and after percutaneous coronar

24 sels in 15 patients with AS before and after TAVI and in 12 control patients.

25 e the shear rate conditions before and after TAVI.

26 and the occurrence and evolution of AR after TAVI by using cardiac MRI.

27 ebral microinfarctions are more common after TAVI compared with SAVR but seem to have no negative eff

28 avalvular leakage is the major concern after TAVI.

29 rocedure DWMRI brain lesions at 2 days after TAVI in potentially protected territories.

30 oke occurring within the first 30 days after TAVI was associated with a 6-fold increase of 30-day mor

31 Patients who died within 30 days after TAVI were excluded.

32 formed at baseline, 2 days, and 7 days after TAVI.

33 A within 3 years (mean 441+/-332 days) after TAVI.

34 nts experience cognitive deterioration after TAVI.

35 The energy of forward waves doubled after TAVI, whereas the backward expansion wave increased by >

36 hs (E3), 1 (E4) year, and 2 years (E5) after TAVI.

37 if </=0.8; negative if >0.8) was found after TAVI (P for interaction <0.001).

38 ation were significantly more frequent after TAVI compared with SAVR.

39 on neurological and cognitive function after TAVI and to devise methods that will provide more comple

40 on the evolution of cognitive function after TAVI.

41 001) of new microinfarcts were greater after TAVI than after SAVR.

42 Improvement in coronary hemodynamics after TAVI was most pronounced in patients without post-TAVI a

43 om 46 +/- 18 mm Hg to 10 +/- 4.5 mm Hg after TAVI and 11.8 +/- 5.7 mm Hg at 5 years (p for post-TAVI

44 9+/-8 years; men, 57%) who suffered IE after TAVI of 7944 patients after a mean follow-up of 1.1+/-1.

45 atients with AS before and immediately after TAVI and in 28 patients without AS.

46 1) patients requiring PPM implantation after TAVI (PPM after TAVI), (2) patients without PPM before o

47 nversely, negative FFR values improved after TAVI (0.92+/-0.06 versus 0.93+/-0.07).

48 y artery pressure immediately improved after TAVI in patients with postcapillary combined (57.8+/-14.

49 tenosis <50) tended toward improvement after TAVI (0.90+/-0.07 versus 0.91+/-0.09; P=0.69).

50 out percutaneous coronary intervention after TAVI.

51 erate-to-severe periprosthetic leakage after TAVI.

52 he difference in volume of new lesions after TAVI in potentially protected territories.

53 erienced stroke during the first month after TAVI.

54 minations before, during, and 3 months after TAVI were used to identify high-intensity transient sign

55 elated quality of life during 6 months after TAVI when compared with SAVR.

56 d in 140 patients within 1 to 3 months after TAVI with the Edwards Sapien XT THV to assess the presen

57 erwent cardiac MRI 1 week and 6 months after TAVI.

58 State Examination before and 6 months after TAVI.

59 a strong predictor of 1-year mortality after TAVI (hazard ratio, 3.28; P=0.005).

60 All-cause mortality after TAVI is higher in patients who develop LBBB than in pati

61 The 30-day mortality after TAVI was 13% and was independently predicted by myocardi

62 onse to treatment and 1-year mortality after TAVI.

63 I), (2) patients without PPM before or after TAVI (no PPM), and (3) patients with PPM before TAVI (PP

64 We compared the outcome after TAVI and SAVR of low-risk patients (European System for

65 of blood products, may improve outcome after TAVI.

66 amic presentation on clinical outcomes after TAVI is unknown.

67 onstrated favorable long-term outcomes after TAVI.

68 AKI occurred in 21% of the patients after TAVI.

69 er baseline risk compared with the PPM after TAVI and no PPM patients (coronary artery disease: 77.1%

70 terval [CI]: 1.51 to 3.72) for the PPM after TAVI group, 2.75 (95% CI: 1.52 to 4.97) for the PPM befo

71 8 patients (27.8%) belonged to the PPM after TAVI group, 48 patients (13.6%) belonged to the PPM befo

72 ality was similar in all 3 groups (PPM after TAVI group: 19.4%, PPM before TAVI group: 22.9%, no PPM

73 iring PPM implantation after TAVI (PPM after TAVI), (2) patients without PPM before or after TAVI (no

74 Prosthetic valve endocarditis (PVE) after TAVI is a serious complication, but only limited data ex

75 LV functional and structural recovery after TAVI.

76 flow velocity with AS that is restored after TAVI, suggesting an acute relief of excess compression i

77 pressure, which was partially restored after TAVI.

78 fore TAVI) and under low shear stress (after TAVI).

79 poral trends, and predictors of stroke after TAVI and evaluate the outcomes of patients with stroke.

80 The occurrence of stroke after TAVI was associated with a strikingly 6-fold increase of

81 tly predicted the occurrence of stroke after TAVI.

82 Overall 30-day and 1-year survival after TAVI were 91.9% (95% CI, 91.1% to 92.8%) and 79.2% (CI,

83 Median survival time after TAVI was 3.4 years (95% confidence interval [CI]: 2.6 to

84 investigation of cognitive trajectory after TAVI is pivotal.

85 try, CA was needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients

86 Nevertheless, FFR variations after TAVI are minor and crossed the diagnostic cutoff of 0.8

87 Functional FFR variations after TAVI changed the indication to treat the coronary stenos

88 secondary end point, new lesion volume after TAVI was lower in the filter group (242 mm3 [95% CI, 159

89 Positive FFR values worsened after TAVI (0.71+/-0.11 versus 0.66+/-0.14).

90 percent diameter stenosis >50 worsened after TAVI (0.84+/-0.12 versus 0.82+/-0.16; P=0.02), whereas F

91 The incidence of IE at 1 year after TAVI was 0.50%, and the risk increased with the use of o

92 ce, 0.67%, 0.50% within the first year after TAVI).

93 ients with or without CA up to 3 years after TAVI were compared.

94 patients throughout the first 2 years after TAVI, despite the high intrinsic risk for cognitive dete

95 ive impairment along the first 2 years after TAVI.

96 andomized trials published in 2019 to assess TAVI in patients with symptomatic severe aortic stenosis

97 Aortic atheroma (TAVI) and concomitant coronary artery bypass grafting (S

98 Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to rec

99 I (no PPM), and (3) patients with PPM before TAVI (PPM before TAVI).

100 75 (95% CI: 1.52 to 4.97) for the PPM before TAVI group, and 2.24 (95% CI: 1.62 to 3.09) for the no P

101 patients (13.6%) belonged to the PPM before TAVI group, and 207 patients (58.6%) belonged to the no

102 ups (PPM after TAVI group: 19.4%, PPM before TAVI group: 22.9%, no PPM group: 18.0%) in unadjusted an

103 The PPM before TAVI patients had a significantly higher baseline risk c

104 3) patients with PPM before TAVI (PPM before TAVI).

105 Classification of CKD stages before TAVI allows risk stratification for early and midterm cl

106 of monocytes under high shear stress (before TAVI) and under low shear stress (after TAVI).

107 statistically significant difference between TAVI and SAVR in early (odds ratio [OR], 1.01 [95% CI, 0

108 tatistically significant differences between TAVI and SAVR patients in short-term readmission rates.

109 The median time between TAVI and stroke was 1 day (interquartile range, 0-6 days

110 -0.1 in AS (P<0.005) and was not restored by TAVI.

111 brovascular events, cognitive status, direct TAVI, cerebral embolism in diffusion-weighted MRI, or th

112 prognostic value of myocardial injury during TAVI.

113 The amount of contrast medium during TAVI was not associated with the development of acute ki

114 lay a major role in events that occur during TAVI, post-procedural events might also be related to a

115 structures in the device landing zone during TAVI is a life-threatening complication that can be trea

116 Twenty-eight TAVI patients (14 SapienXT and 14 CoreValve) were retros

117 been thoroughly investigated in very elderly TAVI cohorts.

118 ected in a multicenter registry encompassing TAVI patients from 2005 until 2010.

119 y be overestimated owing to rapidly evolving TAVI technology.

120 ure of the aortic root in balloon-expandable TAVI is associated with severe prosthesis oversizing.

121 f this complication after balloon-expandable TAVI.

122 tients who suffered symptomatic CO following TAVI of 6,688 patients (0.66%).

123 Symptomatic CO following TAVI was a rare but life-threatening complication that o

124 Very little data exist on CO following TAVI.

125 h (interquartile range: 0 to 72 h) following TAVI.

126 is known about long-term outcomes following TAVI.

127 erspective on these evolving indications for TAVI, discuss relevant available data from clinical tria

128 Also, reasons for readmission for TAVI and SAVR patients were examined and compared.

129 FRANCE TAVI (French Transcatheter Aortic Valve Implantation) is

130 FRANCE TAVI participants were older but at lower surgical risk

131 ioprostheses Established by Catheter [FRANCE TAVI]; NCT01777828).

132 A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in t

133 ed from 95.3% in FRANCE 2 to 96.8% in FRANCE TAVI (p < 0.001).

134 were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively, in FRAN

135 More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR.

136 national prospective French registry (FRANCE TAVI [French Transcatheter Aortic Valve Implantation]),

137 15 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) re

138 The FRANCE TAVI registry provided reassuring data regarding trends

139 om January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Biopr

140 Mean time from TAVI was 6 months (interquartile range, 1-14 months).

141 in daily practice when this third-generation TAVI device is used.

142 for transcatheter aortic valve implantation (TAVI) and its impact on clinical outcomes.

143 of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) for p

144 ing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR), but

145 ing transcatheter aortic valve implantation (TAVI) and to decipher the impact of this peri-procedural

146 ing transcatheter aortic valve implantation (TAVI) and whether it is associated with mortality.

147 of transcatheter aortic valve implantation (TAVI) clinical endpoints to make them more suitable to t

148 ter transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (S

149 by transcatheter aortic valve implantation (TAVI) decreases ventricular afterload and is expected to

150 ter transcatheter aortic valve implantation (TAVI) during the same procedure.

151 in transcatheter aortic valve implantation (TAVI) for high-risk patients with severe aortic stenosis

152 ter transcatheter aortic valve implantation (TAVI) has been associated with poor outcomes, but little

153 Transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic alternative for patie

154 Transcatheter aortic valve implantation (TAVI) has emerged as a valid therapeutic option for youn

155 Transcatheter aortic valve implantation (TAVI) has emerged as an important treatment for patients

156 Transcatheter aortic valve implantation (TAVI) has evolved to a treatment of choice in high-risk

157 Transcatheter aortic valve implantation (TAVI) has revolutionized its treatment, thereby avoiding

158 Transcatheter aortic valve implantation (TAVI) has revolutionized the treatment of symptomatic se

159 ter transcatheter aortic-valve implantation (TAVI) have not been well studied.

160 of transcatheter aortic valve implantation (TAVI) in high-risk patients is leading to the expansion

161 ter transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long

162 out transcatheter aortic valve implantation (TAVI) in patients with low ejection fraction.

163 of transcatheter aortic valve implantation (TAVI) in pure native aortic valve regurgitation (NAVR) f

164 Transcatheter aortic valve implantation (TAVI) is a novel therapy for treatment of severe aortic

165 ter transcatheter aortic valve implantation (TAVI) is a rare complication, which is diagnosed based o

166 Transcatheter aortic valve implantation (TAVI) is an advancing mode of treatment for inoperable o

167 Transcatheter aortic valve implantation (TAVI) is associated with a higher risk of neurological e

168 Transcatheter aortic valve implantation (TAVI) is known to be associated with silent cerebral inj

169 Transcatheter aortic valve implantation (TAVI) is superior to standard medical therapy and noninf

170 ing transcatheter aortic valve implantation (TAVI) present with low-ejection fraction, low-gradient (

171 Transcatheter aortic valve implantation (TAVI) still presents complications: paravalvular leakage

172 Transcatheter aortic valve implantation (TAVI) using the Medtronic CoreValve (MCV) system might r

173 ith transcatheter aortic valve implantation (TAVI) were included.

174 ing transcatheter aortic valve implantation (TAVI) who suffered coronary obstruction (CO).

175 ent transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 (mean age, 81.6+/-6.6 years; 48.

176 of transcatheter aortic valve implantation (TAVI).

177 ter transcatheter aortic valve implantation (TAVI).

178 ful transcatheter aortic valve implantation (TAVI).

179 ter transcatheter aortic valve implantation (TAVI).

180 ter transcatheter aortic valve implantation (TAVI).

181 ing transcatheter aortic valve implantation (TAVI).

182 ing transcatheter aortic valve implantation (TAVI).

183 ter transcatheter aortic valve implantation (TAVI).

184 of transcatheter aortic valve implantation (TAVI).

185 ter transcatheter aortic valve implantation (TAVI).

186 asure for which there is limited evidence in TAVI populations.

187 Physical component score in TAVI increased after 30 days (32.1+/-6.6 versus 38.9+/-7

188 total volume per microinfarct was smaller in TAVI than in SAVR (0.23+/-0.24 versus 0.76+/-1.8 mL; P=0

189 ospective registry study reflected real-life TAVI experience in high-risk elderly patients with aorti

190 tically different for all propensity-matched TAVI and SAVR patients (respective rates, 18.8% and 19.3

191 and therefore a novel therapeutic benefit of TAVI.

192 ould support safe planning and broadening of TAVI.

193 ary hemodynamics and the immediate effect of TAVI.

194 analyze safety, feasibility, and efficacy of TAVI in patients with severe left ventricular dysfunctio

195 re necessary before expanding indications of TAVI toward lower-risk patients.

196 model was used to verify the interaction of TAVI effect with the FFR values.

197 These findings indicate that outcome of TAVI may be improved by more restrictive use of blood tr

198 mporary European trends and good outcomes of TAVI in daily practice when this third-generation TAVI d

199 This analysis aims to describe outcomes of TAVI versus SAVR in low-risk patients.

200 ic computational framework for prediction of TAVI outcomes and possible complications.

201 type did not influence the mortality risk of TAVI-induced LBBB.

202 An increased risk of TAVI-PVE was seen in patients with low implanted valve p

203 ns were associated with an increased risk of TAVI-PVE.

204 Antithrombotic therapy in the setting of TAVI has been empirically determined, and unfractionated

205 The use of TAVI in severe bicuspid aortic valve stenosis, asymptoma

206 efinitions for studies evaluating the use of TAVI, which will lead to improved comparability and inte

207 n procedures performed in the early years of TAVI (2007-2012) to those in the more recent years of TA

208 7-2012) to those in the more recent years of TAVI (2013-2018; both 2.4%; P=1.0).

209 AS or TAVI did not alter diastolic velocity time integral.

210 One hundred eleven patients (TAVI, n=71; SAVR, n=40) were studied.

211 sfemoral procedures, and in 50% of patients, TAVI was performed without aortic balloon valvuloplasty.

212 In younger and low-risk patients, TAVI had an early safety benefit over surgical aortic va

213 ectively from 14 centers that have performed TAVI for NAVR.

214 Post-TAVI MDCT identified THV thrombosis in 5 patients (4%).

215 Post-TAVI MDCT is a valuable tool for the diagnosis of THV th

216 %, life-threatening bleeding of 5%, and post-TAVI pacemaker implantation of 12%.

217 Median relative change in CAAD pre- and post-TAVI was -0.5% (interquartile range, 3.6%).

218 d 1.40 +/- 0.25 cm(2) at 5 years (p for post-TAVI trend <0.01).

219 nd 11.8 +/- 5.7 mm Hg at 5 years (p for post-TAVI trend = 0.06).

220 riod of diastole significantly improved post-TAVI (pre-TAVI 1.88+/-1.0 versus post-TAVI 2.09+/-0.8 [P

221 The change in microvascular resistance post-TAVI was equivalent to that produced by stenting a coron

222 +/-15.47 pre-TAVI to 56.56+/-17.44 cm/s post-TAVI (P=0.003).

223 iod of diastole increased significantly post-TAVI (pre-TAVI, 2.71+/-1.4 mm Hg.cm.s(-1) versus post-TA

224 hereas 2 (40%) did not receive standard post-TAVI dual-antiplatelet therapy.

225 Thus, post-TAVI coronary access (CA) and percutaneous coronary inte

226 with controls, which remained unaltered post-TAVI.

227 d post-TAVI (pre-TAVI 1.88+/-1.0 versus post-TAVI 2.09+/-0.8 [P=0.003]); this was independent of the

228 -TAVI, 2.71+/-1.4 mm Hg.cm.s(-1) versus post-TAVI 3.04+/-1.6 mm Hg.cm.s(-1) [P=0.03]).

229 was most pronounced in patients without post-TAVI aortic regurgitation.

230 Pre-TAVI computed tomography data was available in 28 CO pat

231 creased significantly from 46.24+/-15.47 pre-TAVI to 56.56+/-17.44 cm/s post-TAVI (P=0.003).

232 relative difference in diameter between pre-TAVI CAAD and nominal diameter of the selected prosthesi

233 astole significantly improved post-TAVI (pre-TAVI 1.88+/-1.0 versus post-TAVI 2.09+/-0.8 [P=0.003]);

234 stole increased significantly post-TAVI (pre-TAVI, 2.71+/-1.4 mm Hg.cm.s(-1) versus post-TAVI 3.04+/-

235 dent and downregulated in patients receiving TAVI.

236 Current guidelines recommend TAVI in patients at increased operative risk of death.

237 As a result, TAVI has been explored for other indications.

238 Compared with SAVR, TAVI may have similar or better early and midterm outcom

239 Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment (OB

240 Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) sh

241 Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) tr

242 The SOLVE-TAVI (Comparison of Second-Generation Self-Expandable Ve

243 nts with symptomatic severe aortic stenosis, TAVI has now been explored across the entire spectrum of

244 ed a single-center study that subcategorized TAVI patients into quartiles (Q1 to Q4) defined by enrol

245 The 5-year outcomes following successful TAVI with a balloon-expandable valve were evaluated in 8

246 s is the first study providing evidence that TAVI results in cognitive improvement among patients who

247 s independent of MR severity suggesting that TAVI should not be withheld from symptomatic patients wi

248 The TAVI patients were included prospectively in a dedicated

249 P = 0.01); most bleeding events were at the TAVI access site.

250 Most bleeding at the TAVI puncture site was counted as non-procedure-related.

251 The resolution of high shear stress through TAVI reduces Mac-1 activation, cellular adhesion, phagoc

252 gly growing body of evidence with respect to TAVI and/or surgical aortic valve replacement.

253 ger LA size and those undergoing transapical TAVI.

254 total of 358 patients underwent transapical TAVI with balloon-expandable prostheses.

255 Transfemoral TAVI provided mortality benefits over SAVR in trials.

256 , the incidence of stroke after transfemoral TAVI was 2.4%.

257 l of 10 982 patients undergoing transfemoral TAVI between 2007 and 2018 were included in the current

258 rsely among patients undergoing transfemoral TAVI.

259 aortic valve stenosis underwent transfemoral TAVI.

260 loon-expandable ES stent valve, transfemoral TAVI with the self-expandable MCV prosthesis resulted in

261 rty-three patients treated with transfemoral TAVI underwent cardiac MRI 1 week and 6 months after TAV

262 trial (Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation 2) w

263 , patients were randomly assigned to undergo TAVI with a cerebral protection device (filter group) or

264 ients with no prior history of AF undergoing TAVI and its incidence was increased in patients with la

265 n age 80 +/- 0.6 years; 49% male) undergoing TAVI consented to participate.

266 F-LG patients with >/=moderate MR undergoing TAVI had significantly lower all-cause mortality (hazard

267 However, patients undergoing TAVI are also at high risk for both bleeding and stroke

268 nical outcomes of LEF-LG patients undergoing TAVI is unknown.

269 Among patients undergoing TAVI who did not have an indication for oral anticoagula

270 trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropr

271 In patients undergoing TAVI who were receiving oral anticoagulation, the incide

272 Of 606 consecutive patients undergoing TAVI, 113 (18.7%) patients with LEF-LG severe aortic ste

273 Of 606 consecutive patients undergoing TAVI, 433 (71.4%) patients with severe aortic stenosis a

274 late mortality in LEF-LG patients undergoing TAVI.

275 is prevalent in >50% of patients undergoing TAVI.

276 in level on mortality in patients undergoing TAVI.

277 ients with severe aortic stenosis undergoing TAVI at the University of Leipzig Heart Center.

278 ients with severe aortic stenosis undergoing TAVI, the use of a cerebral protection device reduced th

279 d a subgroup of patients who were undergoing TAVI and did not have an indication for long-term antico

280 istory of atrial fibrillation (AF) underwent TAVI with a balloon-expandable valve.

281 A total of 43 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapol

282 ately one-half of the patients who underwent TAVI because of a high or prohibitive surgical risk prof

283 patients with aortic stenosis who underwent TAVI was conducted.

284 from 642 consecutive patients who underwent TAVI were prospectively collected.

285 the Italian CoreValve Registry who underwent TAVI with the subclavian approach were included.

286 potential procedure difficulties when using TAVI for severe NAVR.

287 ndent predictors of all-cause mortality were TAVI-induced LBBB (hazard ratio [HR], 1.54; confidence i

288 ngest associations for microinfarction were: TAVI (arch atheroma grade: r=0.46; P=0.0001) and SAVR (c

289 derly patients with aortic stenosis, in whom TAVI appeared to be a reasonable option.

290 most common adverse effects associated with TAVI are heart block, vascular complications, and renal

291 st on the long-term outcomes associated with TAVI.

292 vents were observed after SAVR compared with TAVI.

293 We identified 18 patients diagnosed with TAVI-PVE during a median follow-up period of 1.4 years (

294 perable BACKGROUND: Data and experience with TAVI in the treatment of patients with pure severe NAVR

295 new-onset atrial fibrillation was lower with TAVI, but risk for pacemaker implantation, vascular comp

296 term (2- to 5-year) all-cause mortality with TAVI (OR, 1.28 [CI, 0.97 to 1.69]), whereas long-term mo

297 (OR, 0.91 [CI, 0.67 to 1.23]) mortality with TAVI.

298 By using cardiac MRI in patients with TAVI, a significant improvement of LV function, volume,

299 oinflammatory effects that are resolved with TAVI.

300 he increase in forward compression wave with TAVI was related to an increase in systolic velocity tim